다제내성 결핵의 진단과 치료 = Diagnosis and treatment of multidrug-resistant tuberculosis

다국어 초록 (Multilingual Abstract)

Multidrug-resistant tuberculosis (MDR-TB) is a great public health concern worldwide. MDR-TB denotes bacillary resistance to at least isoniazid and rifampicin. Extensively drug-resistant tuberculosis (XDR-TB) is MDR-TB with additional bacillary resistance to any fluoroquinolone and at least one second-line injectable drug. The treatment of MDR-TB requires prolonged administration of a toxic second line anti-tuberculosis drug and generally has poor outcomes. XDR-TB requires more complex treatment and has higher mortality. MDR- and XDR-TB arise because of inadequate or interrupted administration of first-line treatment and can be transmitted in the community. Thus, prevention of the emergence of resistance is the first principle in the management of MDR/XDR-TB. To prevent the emergence of drug resistance and transmission of MDR/XDR-TB, the adequate prescription of an anti-TB drug by a physician and good adherence of patients are essential. In addition, rapid diagnosis of drug resistance using molecular tests such as a line probe assay and Xpert MTB/RIF and the programmatic management of MDR/XDR-TB by designing an effective regimen using available drugs (a newer generation of fluoroquinolone, second-line injectable drugs, second-line oral drugs, and pyrazinamide) based on a guideline are an important strategy for controlling MDR/XDR TB. Despite the long duration of treatment, the treatment success rate of MDR-TB for patients who started treatment in 2009 has been 48% according to the World Health Organization. Thus, to improve the treatment outcomes of MDR/XDR-TB, new drug development is necessary.

참고문헌 (Reference)

1 Bai GH, "Trend of anti-tuberculosis drug resistance in Korea, 1994-2004" 11 : 571-576, 2007

2 Kwon YS, "Treatment out-comes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis" 47 : 496-502, 2008

3 Kim DH, "Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis" AMER THORACIC SOC 178 : 1075-1082, 2008

4 Yoon-Sung Park, "The National Status of Tuberculosis Using Nationwide Medical Records Survey of Patients with Tuberculosis in Korea" 대한결핵및호흡기학회 73 (73): 48-55, 2012

5 "Streptomycin treatment of pulmonary tuberculosis" 2 : 769-782, 1948

6 Torun T, "Side effects associated with the treatment of multidrug-resistant tuberculosis" 9 : 1373-1377, 2005

7 Van Deun A, "Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis" 182 : 684-692, 2010

8 Park SK, "Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea" 8 : 361-368, 2004

9 Boehme CC, "Rapid mole-cular detection of tuberculosis and rifampin resistance" 363 : 1005-1015, 2010

10 Kim HJ, "Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis" EUROPEAN RESPIRATORY SOC JOURNALS LTD 28 : 576-580, 2006

11 World Health Organizaton, "Policy statement: molecular line probe assays for rapid screening of patients at risk of multi-drug-resistant tuberculosis" World Health Organization 2008

12 World Health Organizaton, "Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resist-ance: Xpert MTB/RIF system" World Health Organization 2011

13 Ahuja SD, "Multidrug resistant pulmonary tuberculosis treatment regi-mens and patient outcomes: an individual patient data meta-analysis f 9,153 patients" 9 : e1001300-, 2012

14 Zhang Y, "Mechanisms of drug resistance in Myco-bacterium tuberculosis" 13 : 1320-1330, 2009

15 Chiang CY, "Management of drug-resistant tuber-culosis" 14 : 672-682, 2010

16 Lee M, "Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis" MASSACHUSETTS MEDICAL SOC 367 (367): 1508-1518, 2012

17 Joint Committee for the Development of Korean Guideline for Tuberculosis, "Korean guidelines for tuberculosis" Korea Centers for Disease Control and Prevention 2011

18 Kim HR, "Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis" 45 : 1290-1295, 2007

19 World Health Organizaton, "Guidelines for the programmatic management of drug-resistant tuberulosis. Emergency update 2008" World Health Organization 2008

20 World Health Organizaton, "Guidelines for the programmatic management of drug-resistant tuberulosis, 2011 update" World Health Organization 2011

21 World Health Organizaton, "Global tuberculosis report 2012" World Health Organizaton

22 "Extensively drug-resistant tuberculosis (XDR-TB): recom-mendations for prevention and control" 81 : 430-432, 2006

23 Kim SJ, "Drug-susceptibility testing in tuberculosis: methods and reliability of results" 25 : 564-569, 2005

24 Mitchison DA, "Drug resistance in tuberculosis" 25 : 376-379, 2005

25 Working Group on New TB Drugs, "Drug pipeline" Working Group on New TB Drugs

26 Gler MT, "Delamanid for multidrug-resistant pulmonary tuberculosis" 366 : 2151-2160, 2012

27 Yew WW, "Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong" 124 : 1476-1481, 2003

28 Mahajan R, "Bedaquiline: first FDA-approved tuberculosis drug in 40 years" 3 : 1-2, 2013

29 World Health Organizaton, "Anti-tuberculosis drug resistance in the world. 3rd global report. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance" World Health Organization 2004

30 Korea Centers for Disease Control and Prevention, "Annual report on the notified tuberculosis patients in Korea, 2011" Korea Centers for Disease Control and Prevention 2011